Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Quit Genius
company
About
Quit Genius is a digital clinic for treating nicotine, alcohol, and opioid addictions.
- 51 - 100
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $2.60M
- Industries
- Employee Benefits,Health Care,Medical,Wellness
- Founded date
- Apr 1, 2017
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Quit Genius is the world’s first digital clinic for treating nicotine, alcohol and opioid addictions. Built on the evidence-based approach of Medication-Assisted Treatment (MAT), Quit Genius combines virtual cognitive behavioral therapy (CBT) with approved medication and connected devices to help employers and health plans tackle the high cost of addiction, while improving the lives of their employees and members.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$78.60M
Quit Genius has raised a total of
$78.60M
in funding over 2 rounds. Their latest funding was raised on
Jul 19, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 19, 2021 | Series B | $64M | 1 | — | — | Detail |
| Mar 18, 2020 | Series A | $12M | 1 |
Octopus Ventures
|
— | Detail |
| May 22, 2018 | Seed | $2.60M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Quit Genius is funded by 2 investors.
Octopus Ventures
and Merck
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Octopus Ventures
|
— | Series B |
Merck
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
